Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform th… Read more
Bolt Biotherapeutics (BOLT) - Total Liabilities
Latest total liabilities as of September 2025: $32.95 Million USD
Based on the latest financial reports, Bolt Biotherapeutics (BOLT) has total liabilities worth $32.95 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bolt Biotherapeutics - Total Liabilities Trend (2018–2024)
This chart illustrates how Bolt Biotherapeutics's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bolt Biotherapeutics Competitors by Total Liabilities
The table below lists competitors of Bolt Biotherapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tonner Drones S.A.
PA:ALTD
|
France | €4.89 Million |
|
Tong Hua Holding Public Company Limited
BK:TH
|
Thailand | ฿32.56 Million |
|
Freightos Limited Warrants
NASDAQ:CRGOW
|
USA | $19.77 Million |
|
PARKER-HANNIFIN CO. - Dusseldorf Stock Exchang
DU:PAR
|
Germany | €16.70 Billion |
|
Profusa, Inc. Common Stock
NASDAQ:PFSA
|
USA | $38.21 Million |
|
Equites Property Fund Ltd
JSE:EQU
|
South Africa | ZAC12.99 Billion |
|
Nureca Limited
NSE:NURECA
|
India | ₹259.46 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Bolt Biotherapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bolt Biotherapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bolt Biotherapeutics (2018–2024)
The table below shows the annual total liabilities of Bolt Biotherapeutics from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $42.43 Million | -9.80% |
| 2023-12-31 | $47.04 Million | -16.44% |
| 2022-12-31 | $56.30 Million | -2.25% |
| 2021-12-31 | $57.60 Million | -61.98% |
| 2020-12-31 | $151.49 Million | +60.66% |
| 2019-12-31 | $94.29 Million | +195.42% |
| 2018-12-31 | $31.92 Million | -- |